Matrix metalloproteinase inhibitors: Current developments and future perspectives

Oncologist

Volumn 6, Issue 5, 2001, Pages 415-427

  Hoekstra, R ^a   Eskens, F A L M ^a   Verweij, J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Cancer; Clinical studies; Matrix metalloproteinase inhibitors; Matrix metalloproteinases

Indexed keywords

4 DEDIMETHYLAMINOSANCYCLINE; AE 941; BATIMASTAT; CARBOPLATIN; CP 471358; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; MARIMASTAT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MM 1270; PACLITAXEL; PRINOMASTAT; REBIMASTAT; TANOMASTAT; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CANCER INVASION; CLINICAL TRIAL; ENZYME DEGRADATION; EXTRACELLULAR MATRIX; HUMAN; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL;

CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR MATRIX; HUMANS; MATRIX METALLOPROTEINASES; NEOPLASM INVASIVENESS; TREATMENT OUTCOME;

EID: 0034751435     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.6-5-415     Document Type: Article

References (94)

1. Biology and biochemistry of proteinases in tumor invasion
2. Stimulation of matrix metalloproteinase production by recombinant extracellular matrix metalloproteinase inducer from transfected Chinese hamster ovary cells
3. Expression of gelatinase B and the extracellular matrix metalloproteinase inducer EMMPRIN in benign and malignant pigment cell lesions of the skin
4. Emerging roles for proteinases in cancer
5. Matrix metalloproteinases in angiogenesis: A moving target for therapeutic intervention
6. Changing views of the role of matrix metalloproteinases in metastasis
7. Matrix metalloproteinases: Biologic activity and clinical implications
8. Inhibition by human recombinant tissue inhibitor of metalloproteinases of human amnion invasion and lung colonization by murine B16-F10 melanoma cells
9. Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells
10. Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension
11. MMP-1 is a prognostic marker for hematogenous metastasis of colorectal cancer
12. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma
13. Prognostic significance of metalloproteinases and their tissue inhibitors in patients with small cell lung cancer
14. Association of matrilysin expression with recurrence and poor prognosis in human esophageal squamous cell carcinoma
15. Stromelysin 3: An independent prognostic factor for relapse-free survival in node-positive breast cancer and demonstration of novel breast carcinoma cell expression
16. The next generation of MMP inhibitors. Design and synthesis
17. Design and synthetic considerations of matrix metalloproteinase inhibitors
18. Matrix metalloproteinase inhibitors
19. Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer
20. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts
21. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases
22. Matrix metalloproteinase inhibition attenuates human pancreatic cancer growth in vitro and decreases mortality and tumorigenesis in vivo
23. Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor
24. The matrix metalloproteinase inhibitor batimastat (BB-94) retards human breast cancer solid tumor growth but not ascites formation in nude mice
25. Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice
26. Effects of matrix metalloproteinase inhibitor BB-94 on liver cancer growth and metastasis in a patient-like orthotopic model LCI-D20
27. Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice
28. Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94)
29. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials
30. Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340
31. Combination therapy including a gelatinase inhibitor and cytotoxic agent reduces local invasion and metastasis of murine Lewis lung carcinoma
32. Pharmacokinetics and efficacy of a novel matrix metalloproteinase inhibitor, AG3340, in single agent and combination therapy against B16-F10 melanoma tumors developing in the lung after IV-tail vein implantation in C57BL/6 mice
33. Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: Single agent and combination chemotherapy studies
34. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts
35. Phase 1 trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer
36. Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites
37. Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites
38. Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions
39. Marimastat (BB2516): Current status of development
40. Marimastat in recurrent colorectal cancer: Exploratory evaluation of biological activity by measurement of carcinoembryonic antigen
41. A dose-finding study of marimastat, an oral matrix metalloproteinase inhibitor, in patients with advanced ovarian cancer
42. Marimastat in patients with advanced pancreatic cancer: A dose-finding study
43. Marimastat in advanced progressive colorectal cancer - A dose finding study
44. Marimastat in patients with hormone refractory prostate cancer: A dose finding study
45. Marimastat in patients with advanced cancer of the ovary - A dose finding study
46. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: Selection of a biologically active and tolerable dose for longer-term studies
47. Phase I trial of marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer
48. A pilot study of the safety and effects of the matrix metalloproteinase inhibitor marimastat in gastric cancer
49. A phase I study of AG3340, a matrix metalloproteinase inhibitor, in patients having advanced cancer
50. Comparison of preclinical efficacy and associated plasma concentrations of AG3340, a matrix metalloproteinase inhibitor, with plasma concentrations achieved clinically
51. Inhibition of human breast cancer regrowth and pulmonary metastases by BAY 12-9566 in athymic mice
52. Anti-invasive and anti-metastatic activity of the novel MMP inhibitor BAY 12-9566 in subcutaneous and orthotopic models using the human colon carcinoma, HCT 116
53. Activity of the matrix metalloproteinase inhibitor BAY 12-9566 against murine subcutaneous and metastatic in vivo models
54. Pre-clinical drug safety profile for the anti-metastatic matrix metalloproteinase inhibitory agent BAY 12-9566
55. Phase I pharmacokinetic study of the matrix metalloproteinase inhibitor BAY 12-9566
56. Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566
57. A Phase I dose escalating study of matrix metalloproteinase inhibitor BAY 12-9566 administered orally in patients with advanced solid turnouts
58. BAY 12-9566, a selective, non-peptidic biphenyl inhibitor of matrix metalloproteinases: Summary of phase I clinical and pharmacokinetic results
59. Phase I and pharmacological study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies
60. CGS27023A, a potent and orally active matrix metalloproteinase inhibitor with antitumor activity
61. Matrix metalloproteinase inhibitor CGS27023A inhibited hematogenic metastasis of B16 melanoma cells in both experimental and spontaneous metastasis models
62. A phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer
63. Pharmacodynamic studies of Col-3, a novel matrix metalloproteinase inhibitor, in patients with advanced cancer
64. Protracted daily treatment with COL-3 an oral tetracycline analog, matrix metalloproteinase inhibitor, is feasible: A phase I, pharmacokinetic and biological study
65. Promising new developments in cancer chemotherapy
66. Safety and pharmacokinetics of BMS-275291, a novel matrix metalloproteinase inhibitor in healthy subjects
67. Pharmacokinetic evaluation of BMS-275291, a matrix metalloproteinase inhibitor, in cancer patients
68. A phase I trial of BMS-275291: A novel, non-hydroxamate, sheddase sparing matrix metalloproteinase inhibitor with no dose-limiting arthritis
69. A phase I study of marimastat in combination with doxorubicin and cyclophosphamide in patients with metastatic breast cancer
70. Schedules of 5FU and the matrix metalloproteinase inhibitor marimastat: A phase I study
71. A phase I study of the matrix metalloproteinase inhibitor, marimastat, administered concurrently with carboplatin, to patients with relapsed ovarian cancer
72. Phase IB study of concurrent administration of marimastat and gemcitabine in non-resectable pancreatic cancer
73. Pilot pharmacokinetic study of marimastat in combination with carboplatin/paclitaxel in patients with metastatic or locally advanced inoperable non-small cell lung cancer
74. A pharmacokinetic and pharmacodynamic study of doxorubicin and docetaxel combinations plus marimastat in metastatic breast cancer
75. Phase I study of the matrix metalloproteinase inhibitor AG3340 in combination with paclitaxel and carboplatin for the treatment of patients with advanced solid tumors
76. Phase I study of AG3440, a matrix metalloproteinase inhibitor, in combination with mitoxantrone/prednisone in patients having advanced prostate cancer
77. A phase I and pharmacokinetic study of the oral matrix metalloproteinase inhibitor BAY 12-9566 in combination with paclitaxel and carboplatin
78. Phase I/pharmacokinetic study of the matrix metalloproteinase inhibitor BAY 12-9566 in conjunction with 5-fluorouracil/folinic acid
79. A phase I and pharmacokinetic study of the matrix metalloproteinase inhibitor BAY 12-9566 in combination with doxorubicin and docetaxel in patients with advanced cancer
80. A phase I and pharmacokinetic study of the selective, non-peptidic inhibitor of matrix metalloproteinases BAY 12-9566 in combination with etoposide and carboplatin
81. A phase I study of the matrix metalloproteinase inhibitor MMI270 (previously termed CGS27023A) with 5FU and folinic acid
82. A phase II study of marimastat (BB-2516) in advanced pancreatic cancer
83. Phase I-II study of marimastat (BB2516) in patients with metastatic melanoma
84. A randomized double-bind placebo-controlled study of marimastat in patients with inoperable gastric adenocarcinoma
85. A randomized study comparing marimastat to gemcitabine as first line therapy in patients with non-resectable pancreatic cancer
86. A multicenter, randomized, double-blind, placebo controlled trial of marimastat in patients with glioblastoma multiforme or gliosarcoma following completion of conventional first-line treatment
87. Phase III study of the matrix metalloproteinase inhibitor prinomastat in patients having advanced non-small cell lung cancer
88. Interim results of a phase III study of the matrix metalloproteinase inhibitor prinomastat in patients having metastatic, hormone refractory prostate cancer
89. Development of matrix metalloproteinase inhibitors in cancer therapy
90. A comparison between gemcitabine and the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced pancreatic cancer
91. Anticancer agents targeting signaling molecules and cancer cell environment: Challenges for drug development?
92. Clinical studies in the development of new anticancer agents exhibiting growth inhibition in models: Facing the challenge of a proper study design
93. A metalloproteinase disintegrin that releases tumor-necrosis-α from cells
94. Preclinical and clinical studies of MMP inhibitors in cancer